Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant like ketamine. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development, say NIH researchers.
Examining brain tissue, researchers have identified common gene groups that are disrupted in people with bipolar disorder, schizophrenia and major depression.
A new study reports how well people with depression respond to placebos may determine how well they will respond to antidepressant medications.
A new study of trainee paramedics concludes those most likely to suffer from PTSD or major depression later in their carriers can be spotted during the first week of training.
The study also found coexisting major depression in almost 40 percent of veterans with current war zone PTSD.
Researchers implanted pacemaker electrodes into the medial forebrain bundle of patients suffering from major depression and performed deep brain stimulation. In a matter of days, in six out of seven patients, symptoms such as anxiety, despondence, listlessness and joylessness had improved considerably.
According to a new study, there is no evidence that levels of depressive symptoms vary seasonally.
Scientists have laid bare a novel molecular mechanism responsible for the major depression symptom, anhedonia, the loss of the ability to experience pleasure. The brain circuit involved in this newly elucidated pathway is largely identical between rodents and humans, upping the odds that the findings point toward new therapies for depression and other disorders. Additionally, opinion leaders hailed the study’s inventive methodology, saying it may offer a much sounder approach to testing new antidepressants.